Contagious cancer thrives in dogs by adopting host's genes

January 20, 2011, Imperial College London

An curious contagious cancer, found in dogs, wolves and coyotes, can repair its own genetic mutations by adopting genes from its host animal, according to a new study in the journal Science.

Scientists at Imperial College London have uncovered an unusual process that helps the cancer survive by stealing tiny DNA-containing 'powerhouses' (known as mitochondria) from the cells of the infected animal, to incorporate as its own. They say this may be because genes in the tumour's own mitochondria have a tendency to mutate and degenerate. The results are surprising because mitochondria and their genes are usually only passed from a mother to her offspring.

The findings may have broad implications for halting the spread of similar diseases in other animals and for understanding cancer progression across species. Mitochondrial transfer between genetically distinct cells has previously been observed in the laboratory, but this is the first time it has been demonstrated to occur in nature.

Canine Transmissible Venereal Tumour or CTVT is a very unusual form of cancer that is typically transmitted by mating, though it can also be spread by licking, biting or sniffing tumour-affected areas. The themselves move directly from dog to dog, acting like a parasite on each infected animal. Found in most canine breeds throughout the world, the scientists think CTVT is very similar to the transmissible but more fatal cancer seen in the endangered Tasmanian devils of Australia.

Dr Clare Rebbeck, formerly a PhD student on the project at Imperial College London, now working at Cold Spring Harbor Laboratory in the USA, originally set out to explore how the cancers found in different parts of the world were related to one another, using of DNA samples. However, her analysis showed that the pattern of relationships for the was different to that of the nuclear DNA. In cases the cancers were even more closely related to some dogs than to other some cancers. This finding indicated that the cancers sometimes acquired mitochondria from their hosts.

Professor Austin Burt from the Department of Life Sciences at Imperial College London, who led the research, said: "Our study has revealed that this type of cancer works in a really unexpected way. It raises some really important questions about the progression of other cancers, such as how they repair their own DNA."

The researchers believe that the cancer does not take up new mitochondria with every new host, rather that this functions as an occasional repair mechanism to replace faulty mitochondria. A naturally high rate of genetic mutation in cancers regularly leads to non-functional genes in the CTVT mitochondria, which causes them to lose productivity.

In an earlier study, Imperial's scientists estimated that the earliest CTVT tumour originated from an ancient dog or wolf approximately 10,000 years ago, perhaps when dogs were first domesticated through intensive inbreeding of the more social wolves. Today's results suggest that over this time, the must have evolved the unusual ability to capture from its host animal.

The scientists hope their work can be built upon by medical researchers to advance our knowledge of in humans and other animal species.

More information: Rebbeck et al. "Mitochondrial Capture by a Transmissible Cancer" published in Science on 20 January 2011.

Related Stories

Recommended for you

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jan 23, 2011
My concern is that the military get's a hold of it and tries to develop a human form they can weaponize.
1 / 5 (1) Jan 26, 2011
So that the enemy dies very very slowly? Be realistic here...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.